Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy

International Journal of Dermatology

Volumn 42, Issue 3, 2003, Pages 224-230

  Lowe, Nick J ^a   Gonzalez, John ^a   Bagel, Jerry ^a   Caro, Ivor ^a   Ellis, Charles N ^a   Menter, Alan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; HYBRID PROTEIN;

ANTIBODY TITER; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PSORIASIS VULGARIS; RECURRENT DISEASE; SIDE EFFECT; T LYMPHOCYTE; AGED; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PSORIASIS; RETREATMENT;

AGED; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; RETREATMENT;

EID: 0038546376     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2003.01793.x     Document Type: Article

References (24)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-496.
3. National Psoriasis Foundation. About psoriasis. Available at http://www.psoriasis.org. Accessed April 2002.
4. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
5. Barker JN. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998; 59: 530-533.
6. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999; 341: 1817-1828.
7. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-222.
8. Majeau GR, Meier W, Jimmo B, et al. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753-2767.
9. Sanders ME, Makgoba MW, Sharrow SO, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988; 140: 1401-1407.
10. + T cells is independent of cell activation. Cell Adhes Commun 1999; 7: 267-279.
11. Ellis CN, Krueger GG for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.
12. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
13. Lim KK, Su WP, Schroeter AL, et al. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin Proc 1996; 71: 1182-1191.
14. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399-408.
15. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45: 649-661.
16. DiGiovanna JJ. Systemic retinoid therapy. Dermatol Clin 2001; 19: 161-167.
17. Stern RS, Liebman EJ, Väkevä L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998; 90: 1278-1284.
18. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761.
19. American Cancer Society. Cancer Facts and Figures 2002. Atlanta, GA: American Cancer Society, 2002.
20. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943-949.
21. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-59.
22. Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol 1983; 9: 59-65.
23. Haynes BF, Markert ML, Sempowski GD, et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000; 18: 529-560.
24. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997; 389: 978-981.